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Abstract
Background: Lymph nodes constitute the first site of metastasis for most malignancies, and the
extent of lymph node involvement is a major criterion for evaluating patient prognosis. The CXC
chemokine receptor 4 (CXCR4) has been shown to play an important role in lymph node
metastasis. Nitric oxide (NO) may also contribute to induction of metastatic ability in human
cancers.
Methods: CXCR4 expression was analyzed in primary human breast carcinoma with long-term
follow-up. The relationship between nitrotyrosine levels (a biomarker for peroxynitrate formation
from NO in vivo) and lymph node status, CXCR4 immunoreactivity, and other established clinico-
pathological parameters, as well as prognosis, was analyzed. Nitrite/nitrate levels and CXCR4
expressions were assessed in MDA-MB-231 and SK-BR-3 breast cancer cell lines after induction
and/or inhibition of NO synthesis.
Results: CXCR4 staining was predominantly cytoplasmic; this was observed in 50%(56/113) of the
tumors. Cytoplasmic CXCR4 expression was significantly correlated with nitrotyrosine levels and
lymph node metastasis. Kaplan-Meier survival curves showed that cytoplasmic CXCR4 expression
was associated with reduced disease-free and overall survival. In multivariate analysis, cytoplasmic
CXCR4 expression emerged as a significant independent predictor for overall and disease-free
survival. Cytoplasmic expression of functional CXCR4 in MDA-MB-231 and SK-BR-3 cells was
increased by treatment with the NO donor DETA NONOate. This increase was abolished by L-
NAME, an inhibitor of NOS.
Conclusion: Our data showed a role for NO in stimulating cytoplasmic CXCR4 expression in
vitro. Formation of the biomarker nitrotyrosine was also correlated with CXCR4 expression and
lymph node metastasis in vivo. In addition, cytoplasmic CXCR4 expression may serve as a
significant prognostic factor for long-term survival in breast cancer.
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Background
Nitric oxide (NO) acts as an intercellular secondary mes-
senger in all mammalian organs, participating in vasodil-
atation, neurotransmission, and macrophage-mediated
immunity [1]. It also possesses metastasis-promoting
properties. NO induces vascular endothelial growth factor
(VEGF) expression in cancer cells and neovascularization
in tumors, which may promote the metastatic ability of
tumor cells [2]. Previously we reported that NO induces
expression of the lymphangiogenic factor VEGF-C in vitro
and in vivo, and may play an important role in lymph
node metastasis in breast cancer [3]. The effects of NO are
mediated in part by its metabolites, such as peroxynitrite.
Peroxynitrite can oxidize and nitrate DNA as well as tyro-
sine in proteins to produce nitrotyrosine [4]. Thus the
presence of nitrotyrosine in tissues has been used as a
biomarker for peroxynitrite formation in vivo from NO.
Metastasis of cancer cells is a complex process involving
invasion, hemangiogenesis, lymphangiogenesis, traffick-
ing of cancer cells through blood or lymph vessels,
extravasations, organ-specific homing, and growth.
Recent evidence suggests that metastatic breast cancer cells
overexpress CXC chemokine receptor 4 (CXCR4), and
that CXCR4 plays a critical role in the homing of cancer
cells to specific metastatic sites [5]. The CXCR4 ligand
CXCL12 was found to be expressed in liver, bone marrow,
lung, and lymph nodes. Furthermore, metastasis of breast
cancer cells to regional lymph nodes and lungs in immu-
nodeficient mice were inhibited by a neutralizing anti-
body against CXCR4 [5]. Previous studies also
demonstrated that up-regulated CXCR4 expression in
human breast cancer is correlated with lymph node
metastasis and unfavorable prognosis [6,7]. However, the
mechanisms of regulation of CXCR4 expression are
largely unknown. We considered the possibility that NO
as an inflammatory stimulant is involved in the expres-
sion of CXCR4 because NO has been shown to up-regu-
late the expression of prometastatic and angiogenic genes
including VEGF [2], VEGF-C [3], and VEGF-D [8]. In
experimental tumor models, a contributory role of NO in
tumor metastasis has also been demonstrated [9]. In addi-
tion, signal-activated transcription factor NF-kappa B,
which is linked to NO signaling pathways, has been
shown to up-regulate the expression of CXCR4 and to
mediate CXCL12-induced T cell migration [10,11].
Recently a positive correlation between lymph node
metastasis and a recombination of CXCR4, VEGF, and
MMP-9 was reported [12]. This correlation may become
more important as VEGF had been reported to promote
breast carcinoma invasion in an autocrine manner by reg-
ulating CXCR4 [13], and at the same time CXCR4 pro-
motes VEGF-mediated tumor angiogenesis [14]. An
enhanced-aggressiveness for lymph node metastasis by
recombination of VEGF-C and CXCR4 may be also specu-
lated.
In this study, we examined how CXCR4 expression relates
to nitrotyrosine formation and lymph node metastasis in
human breast cancer tissues, and further investigated
whether CXCR4 has any value or relevance for predicting
disease outcome. We then showed that incubation of
MDA-MB-231 and SK-BR-3 breast cancer cells with an NO
donor results in induction of cytoplasmic CXCR4 expres-
sion. This induction is significantly inhibited by addition
of the NOS inhibitor L-NAME.
Methods
Patients and tumor samples
This study was approved by the review board of the
Wakayama Medical University Medical Ethics Committee
and informed consent was obtained from each of the
patients. Archival paraffin-embedded specimens of inva-
sive breast cancer from 113 patients who were diagnosed
and treated in the Osaka Police Hospital, Japan, between
1981 and 1992, were selected as described previously [3].
None of these cases had a family history of breast cancer
or malignancy in first-degree relatives as determined by
questioning at the time of admission for surgery. The
patients had received mastectomy with axillary lymph
node dissection. All women were apparently free of dis-
tant metastasis. All cases received post-operative adjuvant
therapy consisting of combination chemotherapy and
hormone treatment. The results of immunostaining for
ER, PgR, c-erbB-2, p53, and VEGF-C were obtained from
our pathological data file [3]. The size of the primary
tumor was determined from the surgical specimen.
Lymph node metastasis was determined by counting the
number of axillary lymph nodes with histological evi-
dence of metastatic breast carcinoma. Histological typing
and histological grading were done according to the WHO
classification [15], and the Nottingham method (Bloom
Richardson) [16]. Patient and tumor characteristics are
shown in Table 1. The median age at diagnosis for the 113
patients was 51 years (range, 24–87 years). Fifty-eight per-
cent of the patients were younger than 50 years (n = 65),
and 52% (n = 59) of the patients had lymph node metas-
tasis at the time of surgery. Twenty-six percent of the
patients had distant organ metastasis during the follow-
up period (n = 29).
Immunohistochemistry
For immunostaining, 4-micrometer thick paraffin sec-
tions were de-paraffinized, placed in a solution of 97%
methanol and 3% hydrogen peroxide for 5 min, then
autoclaved for antigen retrieval. After washing in PBS, the
slides were treated for 20 min with Protein Block Serum-
free (DAKO Cytomation, Carpinteria, CA, USA). This was
followed by an overnight incubation at 4°C in a humidi-BMC Cancer 2008, 8:340 http://www.biomedcentral.com/1471-2407/8/340
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fied chamber with a 1:30 diluted anti-human CXCR4 rab-
bit antibody (Abcam Ltd., Cambridge, UK). After the
overnight treatment, to avoid the nonspecific biotin reac-
tion, Histofine Simple Stain MAX PO (NICHIREI, Tokyo,
Japan) was used as the second antibody for 60 min
according to the manufacturer's instructions. Color was
developed using diaminobenzidine with 0.01% hydrogen
peroxide. Hematoxylin was used as a counterstain. For the
negative control, all reagents except for the primary anti-
body were used.
The immunohistochemical scoring was performed
blindly by 3 pathologists (HY, MT, and YN) who had no
clinical knowledge of the patients. The immunostained
sections were scanned by light-microscopy, and evalua-
tion of CXCR4 expression was performed according to
Cabioglu et al [6]. The intensity, staining percentage, and
pattern of staining (nuclear and cytoplasmic) were
assessed for CXCR4. The intensity was scored as low, mod-
erate, and strong compared with background staining.
The percentages of positive cells were estimated by calcu-
lating the ratio of the positively stained invasive tumor
cells to the total invasive cells. Nuclear versus cytoplasmic
location of expression was also noted in each sample. The
staining patterns of tumors for CXCR4 was defined as
high cytoplasmic expression (moderate and >50%, or
strong and >30% cytoplasmic expression) or predomi-
nantly nuclear expression (at least 80% nuclear expres-
sion) by using the criteria according to Cabioglu et al [6].
Cell culture
The MDA-MB-231 and SK-BR-3 breast carcinoma cell
lines were purchased from the American Type Culture
Collection (ATCC, Rockville, MD, USA). MDA-MB-231
cells were maintained at 37°C in 95% air and 5% CO2, as
monolayers in tissue culture dishes containing DMEM
medium (Invitrogen, Tokyo, Japan) supplemented with
10% heat-inactivated fetal calf serum (FCS) (HyClone,
South Logan, UT, USA). SK-BR-3 cells were maintained at
37°C in 95% air and 5% CO2, as monolayers in tissue cul-
ture dishes containing McCoy's 5A medium (Invitrogen)
supplemented with 10% heat-inactivated FCS (HyClone).
For the experiments, 6 cm tissue culture plates (Corning
Inc, Corning, NY, USA) were seeded with 3 × 105 cells in
3 ml of medium + 10% FCS. Media were changed on day
3, and when the cells were subconfluent (day 5). 5 mM L-
NAME (Sigma-Aldrich, Tokyo, Japan), if administered,
was added 2 h before 1 mM DETA NONOate (Cayman
Chemical, Ann Arbor, MI, USA). These concentrations of
L-NAME or DETA NONOate had no effect on cell viability
as measured by the CellTiter 96 Aqueous One Solution
Cell Proliferation Assay (Promega, Madison, WI, USA)
(data not shown).
Determination of CXCR4 mRNA expression
After DETA NONOate (half-life of 20 h at 37°C) admin-
istration, each cell line was incubated along with DETA
NONOate with or without L-NAME for 4, 6, 8, 12, 16, and
24 h. Total RNA was extracted using Trizol (Invitrogen)
Table 1: The relationship between CXCR4 expression and other parameters
CXCR4 Positivity CXCR4 positivity
Factor Cytoplasm p value Nucleus p value
Age <50 28/65 (43%) 0.1298 17/65 (26%) 0.8896
51 28/48 (58%) 12/48 (25%)
Histology Ductal 54/104 (52%) 0.1620 28/104 (27%) 0.4432
Others 2/9 (22%) 1/9 (11%)
Tumor size pT1 15/34 (44%) 0.5395 11/34 (32%) 0.3487
pT2-4 41/79 (52%) 18/79 (23%)
ER Negative 24/45 (53%) 0.5671 11/45 (24%) 0.8302
Positive 32/68 (47%) 18/68 (26%)
PgR Negative 27/51 (53%) 0.5729 12/51 (24%) 0.6710
Positive 29/62 (47%) 17/62 (27%)
c-erbB-2 Negative 39/81 (48%) 0.6800 22/81 (27%) 0.6387
Positive 17/32 (53%) 7/32 (22%)
p53 Negative 36/73 (49%) 0.9445 22/73 (30%) 0.1789
Positive 20/40 (50%) 7/40 (18%)
Histological I and II 31/66 (47%) 0.5695 16/66 (24%) 0.8273
Grade III 25/47 (53%) 13/47 (28%)
Nitrotyrosine formation Low 10/48 (21%) <0.001 11/48 (23%) 0.6649
High 46/65 (71%) 18/65 (28%)
Distant metastasis Negative 34/84 (40%) 0.0012 22/84 (26%) 1.0000
Positive 22/29 (76%) 7/29 (24%)BMC Cancer 2008, 8:340 http://www.biomedcentral.com/1471-2407/8/340
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according to the protocol provided by the manufacturer.
After treatment with DNA-free™ DNase (Ambion, Austin,
TX, USA), mRNA was reverse-transcribed for single strand
cDNA using Oligo-(dT)20 primer and Thermoscript (Invit-
rogen, Tokyo, Japan) as described previously [3]. CXCR4
transcription was measured by quantitative real-time PCR
of the resulting cDNA, using universal TaqMan PCR rea-
gents, and an ABI Prism 7000 sequence detector equipped
with a 96-well thermal cycler (Perkin-Elmer Applied Bio-
systems, Foster City, CA, USA). The primer and probe mix-
tures for CXCR4 and GAPDH were purchased from
Perkin-Elmer Applied Biosystems, and PCR was carried
out according to the manufacturer's protocol. CXCR4
mRNA expression was quantitated relative to control cells
(treated with neither DETA NONOate or L-NAME) based
on a real-time PCR standard curve constructed with seri-
ally diluted solutions of a CXCR4 cDNA-containing plas-
mid as templates. All experiments were performed in
triplicate, even though amplification results have been
shown to be very stable and tube-to-tube-variability very
low. Mean values were used for statistical testing. The
GAPDH transcript levels of each sample were also moni-
tored; tube-to-tube-variability was very low for these
amplifications as well (data not shown).
Determination of CXCR4 protein expression
For the determination of CXCR4 protein production, each
cell line was incubated for 12 h after DETA NONOate
administration with or without L-NAME, because the
peak time of CXCR4 mRNA expression after DETA NON-
Oate administration was 6–12 h in MDA-MB-231 cells
and 8 h in SK-BR-3 cells, and harvested as described
above. Cell lysates were prepared using NE-PER™ Nuclear
and Cytoplasmic Extraction Reagents (Pierce, Rockford,
IL, USA) containing Halt™ Protease Inhibitor Cocktail
(Pierce). For Western blot analysis of CXCR4, 40 micro-
gram samples of nuclear extracts or cytoplasmic fractions
were separated by electrophoresis on 10–20% SDS poly-
acrylamide gels and transferred to PVDF membranes by
electroblotting as described previously [3]. The mem-
brane was blocked with 5% skim milk in PBS for 1 h at
room temperature, incubated overnight with anti-human
CXCR4 rabbit antibody (Abcam), rinsed with PBS, and
labeled with peroxidase-conjugated anti-rabbit secondary
antibody (Dako Cytomation, Denmark) for 1 h at room
temperature. The signals were visualized using the Lumi-
GLO Reserve chemiluminescence substrate kit (KPL, Inc,
Gaithersburg, MD, USA) and recorded by luminocapture
(ATTO, Tokyo, Japan). Anti-beta-2-microglobulin anti-
body (Dako Cytomation) was used for the internal con-
trol of cytoplasmic extract. Anti-transcript factor IID
(Upstate, Lake Placid, NY) was used for the internal con-
trol of nuclear extract. To compare levels of proteins, the
density of each band was measured by densitometry.
Chemoinvasion assay
Migration assay of each cell type was assayed in a BD
Matrigel™ Invasion Chamber 24-well plate (BD Bio-
sciences, Bedford, MA, USA). Briefly, the upper compart-
ment of the chamber was seeded with 5 × 103 cells, and
the lower compartment of the chamber was loaded with
medium. Medium in the upper compartment of the
chamber was changed (day 3), and 5 mM L-NAME, if
administered, was added 2 h before 1 mM DETA NON-
Oate. At the same time, the lower compartment of the
chamber was loaded with different concentrations of
recombinant human (rh) CXCL12 or without rhCXCL12
(R&D Systems, Minneapolis, MN, USA). The two com-
partments were separated by Matrigel (10 micrometer
thickness and 8 micrometer pore size). Uncoated mem-
branes were used as a control for non-invasive cell migra-
tion, in accordance with the manufacturer's directions.
After the incubation (day 5), the chamber was removed,
and cells that had migrated to the bottom of the mem-
brane were fixed and stained in Cyto Quick Solution
(Muto Pure Chemical, Tokyo, Japan) and counted by light
microscopy. The percentage of invading cells after incuba-
tion (% Invasion) was calculated as (Matrigel)/(Control
membrane), according to the manufacturer's protocol.
Statistics
The effects of drug treatment were analyzed by ANOVA.
Fisher's exact test was used to examine the association of
CXCR4 expression with age, histological type, tumor size,
lymph node metastasis, ER, PgR, c-erbB-2, p53, histologi-
cal grade, nitrotyrosine levels, and distant organ metasta-
sis, and also to examine the correlation of lymph node
metastasis with CXCR4 expression, VEGF-C expression,
and a recombination of cytoplasmic CXCR4 and VEGF-C
expression. A p value less than 0.05 was considered signif-
icant. A software package (JMP IN 5.1.1, SAS Institute,
Cary, NC, USA) was used for all statistical testing and
management of the database.
Results
CXCR4 expression in breast cancer tissue
In our series on immunostaining of CXCR4, cytoplasmic
staining was more prominent than nuclear staining. Cyto-
plasmic staining with a nuclear component (Figure 1A)
was observed in 20% (23/113) of the tumors, nuclear
staining predominantly (Figure 1B) in 5% (6/113), cyto-
plasmic staining predominantly (Figure 1C) in 29% (33/
113), and no staining in 45% (51/113). In addition to
tumor cells, CXCR4 staining was also observed in inflam-
matory cells.BMC Cancer 2008, 8:340 http://www.biomedcentral.com/1471-2407/8/340
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Cytoplasmic CXCR4 expression is correlated with 
nitrotyrosine levels and lymph node/distant organ 
metastasis
We previously reported that nitrotyrosine formation was
detected by immunohistochemistry in all invasive breast
carcinomas [3]. The intensity of nitrotyrosine immunos-
taining was evaluated by dividing the cytoplasmic stain-
ing reaction into four groups: 1 = weak; 2 = moderate; 3 =
strong; and 4 = very strong. The fraction of immunos-
tained cells was scored as follows: 1 = <25%; 2 = 25–50%;
3 = 50–75%; and 4 = >75% of tumor cells showing cyto-
plasmic staining. These scores were then divided into two
groups as low-grade (2–4) and high-grade (5–8) for statis-
tical testing. As we reported previously [3], high-grade
nitrotyrosine staining was observed in 57.5% (65/113) of
the breast cancer patients, and its expression was signifi-
cantly correlated with lymph node metastasis (p < 0.001).
As shown in Table 1, cytoplasmic CXCR4 expression was
correlated with high-grade nitrotyrosine staining (p <
0.001) and distant organ metastasis (p = 0.0012). There
was no significant correlation between cytoplasmic as
well as nuclear CXCR4 expressions and other clinico-
pathological factors. As shown in Table 2, lymph node
metastasis was correlated with cytoplasmic CXCR4 expres-
sion (p = 0.0144), VEGF-C expression (p = 0.0123), and
recombination of cytoplasmic CXCR4 and VEGF-C
expression (p = 0.0081).
Cytoplasmic CXCR4 expression is correlated with patients' 
survival
Survival analysis was performed on 113 patients and the
following variables were examined: cytoplasmic or
nuclear CXCR4 expression, tumor size, lymph node
metastasis, hormonal status, c-erbB-2, p53, histological
CXCR4 expression in human breast carcinoma tissue Figure 1
CXCR4 expression in human breast carcinoma tissue. (A) The staining pattern of CXCR4 was cytoplasmic staining 
with a nuclear component. (B) In some cases carcinoma cells showed positive staining predominantly in the nuclei or (C) pre-
dominantly in the cytoplasm.BMC Cancer 2008, 8:340 http://www.biomedcentral.com/1471-2407/8/340
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grade, and nitrotyrosine formation. As shown in a previ-
ous report [3], univariate survival analysis showed that
tumor size, lymph node metastasis, ER status, c-erbB-2,
and high-grade nitrotyrosine staining were of significant
prognostic value for DFS. Lymph node metastasis and
high-grade nitrotyrosine staining were of significant prog-
nostic value for OS. In this study, cytoplasmic CXCR4
expression was of significant prognostic value for DFS (p
= 0.0020) and OS (p = 0.0002). As shown in Table 3, mul-
tivariate Cox regression analysis of all covariates focusing
on DFS identified the following as independent signifi-
cant prognostic factors: tumor size, p = 0.0347: lymph
node metastasis, p = 0.0007: and cytoplasmic CXCR4
expression, p = 0.0465. Similarly, lymph node metastasis
and cytoplasmic CXCR4 expression were identified as
independent prognostic factors for OS (lymph node
metastasis; p = 0.0107, cytoplasmic CXCR4 expression; p
= 0.0263).
Effects of NO on CXCR4 expression
To examine the effect of NO on CXCR4 induction, both
MDA-MB-231 and SK-BR-3 cells were treated with the NO
donor DETA NONOate. As we described previously [3], a
significant increase in nitrate/nitrite production was
observed in the supernatants after stimulation with DETA
NONOate. Pre-treatment of the cells with the NOS inhib-
itor L-NAME significantly inhibited this increase. As
shown in Figures 2A and 2B, significant increases in
CXCR4 mRNA and cytoplasmic protein expressions were
observed after stimulation with DETA NONOate. Nuclear
CXCR4 protein expression was unchanged in both cell
lines. Pretreatment with L-NAME substantially inhibited
all of these effects of DETA NONOate on CXCR4 expres-
sion.
Table 2: The relationship between lymph node metastasis and other parameters
Lymph node metastasis
Factor Negative Positive p value
Cytoplasmic CXCR4 20/54 (37%) 36/59 (61%) 0.0144
Nuclear CXCR4 16/54 (30%) 13/59 (22%) 0.3941
VEGF-C 39/54 (72%) 54/59 (92%) 0.0123
Cytoplasmic CXCR4 + VEGF-C 18/54 (33%) 35/59 (59%) 0.0081
Table 3: Results of multivariate Cox regression analysis of disease-free survival (DFS) and overall survival (OS) in 113 breast cancer 
cases
Odds ratio (95% CI) Odds ratio (95%CI)
Variable DFS p value OS p value
Tumor size pT1 1.0 (referent) 0.0347 1.0 (referent) 0.1299
pT2-4 2.91 (1.08–7.82) 2.08 (0.81–5.39)
Lymph node metastasis Negative 1.0 (referent) 0.0007 1.0 (referent) 0.0107
Positive 5.43(2.03–14.49) 3.32 (1.32–8.32)
ER Positive 1.0 (referent) 0.8809 1.0 (referent) 0.3942
Negative 1.07 (0.46–2.47) 1.50 (0.59–3.83)
PgR Positive 1.0 (referent) 0.4759 1.0 (referent) 0.0643
Negative 1.34 (0.60–3.02) 2.27 (0.95–5.39)
c-erbB-2 Negative 1.0 (referent) 0.6208 1.0 (referent) 0.7099
Positive 1.19 (0.59–2.39) 1.16 (0.53–2.56)
p53 Negative 1.0 (referent) 0.5545 1.0 (referent) 0.5544
Positive 1.25 (0.60–2.62) 1.30 (0.55–3.07)
Histological grade I and II 1.0 (referent) 0.2145 1.0 (referent) 0.1295
III 1.55 (0.78–3.12) 1.81 (0.84–3.91)
Nitrotyrosine formation Low 1.0 (referent) 0.1247 1.0 (referent) 0.0669
High 2.03 (0.82–5.02) 2.76 (0.93–8.20)
CXCR4 (cytoplasm) Negative 1.0 (referent) 0.0465 1.0 (referent) 0.0263
Positive 2.08 (1.01–4.26) 2.59 (1.12–6.02)
CXCR4 (nucleus) Negative 1.0 (referent) 0.7341 1.0 (referent) 0.9446
Positive 1.15 (0.52–2.55) 1.03 (0.45–2.39)BMC Cancer 2008, 8:340 http://www.biomedcentral.com/1471-2407/8/340
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NO regulates CXCL12-mediated Invasion of breast cancer 
cells
To determine the role of NO in cellular response to the
CXCR4 ligand CXCL12, we examined the effect of L-
NAME on rhCXCL12- and DETA NONOate-induced in-
vitro Matrigel invasion by MDA-MB-231 and SK-BR-3
cells (Figure 3). rhCXCL12 produced a dose-dependent
increase in invasiveness, which was inhibited in cells pre-
treated with L-NAME.
Discussion
NO is involved in various regulatory functions in vivo. It
has diverse physiological and pathophysiological roles,
such as vasodilatation, neurotransmission, and host
defense [1]. As a free radical, NO is reactive and serves as
antibacterial and antitumor mediators [17,18]. Also, NO
reportedly plays a role in experimental models of tumor
cell metastasis [2,9]. Previous reports have shown that NO
induces lymphangiogenic factor VEGF-C or VEGF-D
expressions in vitro and in vivo, and may play an impor-
tant role in lymph node metastasis in cancers [3,8,19].
CXCR4 is the physiological receptor for CXCL12, which
belongs to a chemokine family that has potent chemotac-
tic activity for lymphocytes. It is well known that periph-
eral lymphocytes preferentially localize to peripheral
lymphoid tissues, such as lymph nodes, which is called
the homing phenomenon [20]. Recent evidence suggests
that metastatic breast cancer cells overexpress CXCR4 and
that this receptor plays a critical role in homing of cancer
cells at specific metastatic sites [5].
In this study, immunohistochemistry revealed that cyto-
plasmic CXCR4 expression was significantly correlated
with nitrotyrosine levels, lymph node metastasis, and dis-
tant organ metastasis in human breast cancer. The NO
donor DETA NONOate induced cytoplasmic expression
of functional CXCR4 protein expression in breast cancer
cell lines. These results may support a possible connection
between cytoplasmic CXCR4 expression and nitrotyrosine
formation in human breast cancer. Consistent with up-
regulation of CXCR4 expression by NO, 71% of the high-
nitrotyrosine patients and only 21% of the low-nitrotyro-
sine patients were positive for cytoplasmic CXCR4.
Although this is lower than the overall percentage of cyto-
plasmic expression of CXCR4 (49%), it indicates that
other factors are also involved in regulating the expression
of this receptor. As it has been previously reported that
NF-kappa B [10], c-erbB-2 [21], or hypoxia-inducible fac-
tor 1 [22] induce CXCR4 expression, these factors may
account for CXCR4 positive cases with low levels of nitro-
tyrosine. In our study, contrary to other reports, there was
no significant correlation between CXCR4 expression and
c-erbB-2 positivity [7,21]. It has been reported that using
anti-CXCR4 monoclonal antibodies may result in an
incomplete detection of CXCR4 molecules because of the
multiple CXCR4 conformations [23], which may account
for the discrepancy between our results using a polyclonal
Effects of NO on CXCR4 expression Figure 2
Effects of NO on CXCR4 expression. Both MDA-MB-231 and SK-BR3 cells were treated with 1 mM DETA NONOate in 
the presence or absence of 5 mM L-NAME for various time periods and prepared for (A) real-time RT PCR analysis, and (B) 
western blot analysis, as described in Materials and Methods. Determinations were performed in triplicate and expressed as 
the mean of three experiments ± SD. Data are expressed as fold increase relative to control (untreated) cells. * indicates sig-
nificant difference (p < 0.05) from control and/or L-NAME-treated cells.
ABBMC Cancer 2008, 8:340 http://www.biomedcentral.com/1471-2407/8/340
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antibody and earlier studies using monoclonal antibod-
ies. Furthermore, lymph node metastasis was correlated
with cytoplasmic CXCR4 expression, VEGF-C expression,
and recombination of cytoplasmic CXCR4 and VEGF-C
expression in this study. Recombination of cytoplasmic
CXCR4 and VEGF-C expression was correlated with
lymph node metastasis more strongly than cytoplasmic
CXCR4 only or VEGF-C only. Similar to the relationship
between VEGF and CXCR4, CXCR4 may be involved in
promoting VEGF-C-mediated tumor lymphangiogenesis
or invasiveness of cancer cells.
In addition, the NO donor DETA NONOate induced
CXCR4 mRNA and cytoplasmic protein expression in the
MDA-MB-231 and SK-BR-3 breast cancer cell lines. In a
chemoinvasion assay, CXCL12-induced invasiveness was
observed with both cell lines after treatment with DETA
NONOate. All of these responses were significantly inhib-
ited in the presence of the NOS inhibitor L-NAME. A sig-
nificant increase in nitrate/nitrite production in the
supernatants after stimulation with DETA NONOate was
also observed, and treatment of cells with L-NAME sub-
stantially inhibited this increase as well. Our results sug-
gest that cytoplasmic CXCR4 expression may be regulated
by NO in breast cancer cells. In this study, although
CXCL12 induced the chemoinvasion of breast cancer cells Figure 3
CXCL12 induced the chemoinvasion of breast cancer cells. Cells were seeded into the upper compartments of 
Matrigel Invasion Chambers as described in Materials and Methods. Uncoated or Matrigel-coated membranes separated the 
upper from the lower compartment containing the indicated concentrations of CXCL12. Cells were treated with DETA 
NONOate with or without L-NAME, and two days later, cells that had migrated to the bottom of the membrane were stained 
and counted. The percentage of invasive cells (% Invasion) was calculated as the number of cells penetrating the Matrigel-
coated membranes divided by the number penetrating the uncoated membranes. Determinations were performed in triplicate 
and expressed as the mean of three experiments ± SD. * indicates significant difference (p < 0.05) from L-NAME-treated cells.
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CXCR4 mRNA expression in SK-BR-3 cells responded well
to NO, CXCR4 protein expression was not comparably
altered. Inasmuch as SK-BR-3 cells may be more sensitive
in its response to NO than MDA-MB-231 cells, an expla-
nation of the differential response in SK-BR-3 cells eludes
us, and remains a subject for future studies. We performed
the migration assay without the use of Matrigel, however,
there was no up-regulation of NO-induced migration
activity (data not shown). This may be due to a previous
report which found that NO decreased RhoA activity [24],
which is a well-known activator of cancer cell motility.
Because CXCR4 enhances cancer invasiveness by matrix
metalloprotease-13 [25], which is important for invasion
of cancer cells by degrading extracellular matrix, this data
may support our results of enhanced-invasiveness via NO-
CXCR4 signaling.
Another question of practical importance was whether
measurement of cytoplasmic CXCR4 expression has any
value or relevance with respect to predicting the disease
course in breast carcinomas. In our results, survival curves
determined by the Kaplan-Meier method and univariate
analysis demonstrated that cytoplasmic CXCR4 expres-
sion was negatively associated with both DFS and OS. Fur-
thermore, multivariate analysis using the Cox stepwise
regression analysis demonstrated that cytoplasmic CXCR4
expression was still correlated with poor DFS and OS after
consideration of other prognostic factors. Therefore, cyto-
plasmic CXCR4 expression appears to be a reliable prog-
nostic biomarker. Although we reported previously that
high-grade nitrotyrosine formation may become a useful
prognostic indicator for OS [3], high-grade nitrotyrosine
staining was not identified as an independent prognostic
factor for OS in this study (p = 0.0669). It may be influ-
enced by cytoplasmic CXCR4 positivity.
Cytoplasmic and nuclear CXCR4 expression in cancer
cells has been described in various cancers [6,26,27]. In
our study, cytoplasmic CXCR4 expression was thought to
be critical for lymph node metastasis and the patients'
poor prognosis in comparison with nuclear CXCR4
expression. CXCR4 localization at the plasma membrane
and intracellular vesicle (cytoplasm) were observed in leu-
kocyte cell lines with enforced CXCR4 expression and
CXCL12 induced polarization of CXCR4 to the edge of
migrating leukocyte cells [28]. Thus, cytoplasmic CXCR4
expression in cancer cells may be more important for
migration of cancer cells, leading in turn to lymph node
metastasis and poor prognosis. Although nuclear CXCR4
expression occurs in normal and cancer tissues [7], its
function is unknown. As it has been reported that a splice
variant of one kind of chemokine lacking the signal pep-
tide is translocated in the nucleus [29], nuclear CXCR4
accumulation may lack a signal peptide and may not be
functional.
Recently Balabanian et al demonstrated that CXCL12 can
also be a ligand for CXCR7 [30]. Previous report also
showed that CXCR7 expression in tumor cells supports
cell growth, survival advantage, and increased adhesion
properties, and also causes in vivo tumor growth in ani-
mal models [31]. Since CXCL12 is expressed preferentially
in lymph nodes, this may support our data that CXCR4
expression was significantly correlated with lymph node
metastasis in human breast tumor samples. As CXCR7
expression also promotes cancer metastasis in breast can-
cer [32], it would be important to investigate the correla-
tion between CXCR4 and CXCR7 in breast cancer in
future studies.
Conclusion
Nitric oxide induces cytoplasmic expression of functional
CXCR4 expression in vitro and in vivo. Cytoplasmic
CXCR4 expression is significantly associated with lymph
node metastasis and high nitrotyrosine levels. NO regula-
tion of CXCR4 expression may play an important role in
lymph node metastasis in breast cancer. Furthermore,
cytoplasmic CXCR4 expression may serve as a significant
prognostic factor for long-term survival in breast cancer.
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